Abstract:Background: Syndrome of inappropriate antidiuresis (SIAD) is one of the most frequent causes of euvolemic hyponatremia (serum sodium levels < 135 mEq/L) and it represents more than 35% of hyponatremia cases in hospitalized patients. It is characterized by an inappropriate vasopressin (AVP)/antidiuretic hormone (ADH) secretion, which occurs independently from effective serum osmolality or circulating volume, leading to water retention via its action on type 2 vasopressin receptor in the distal renal tubules. Corpus callosum agenesis (CCA) is one of the most common congenital brain defects, which can be associated to alterations in serum sodium levels. This report presents a rare case of chronic hyponatremia associated with SIAD in a woman with CCA, whose correction of serum sodium levels only occurred following twice-daily tolvaptan administration. Case presentation: A 30-year-old female was admitted to our hospital for non-acute hyponatremia with dizziness, headache, distal tremors, and concentration deficits. She had profound hyponatremia (Na 121 mmol/L) with measured plasma hypo-osmolality (259 mOsm/Kg) and urinary osmolality greater than 100 mOsm/Kg (517 mOsm/Kg). She presented clinically as normovolemic. After the exclusion of other causes of normovolemic hyponatremia, such as hypothyroidism and adrenal insufficiency, a diagnosis of SIAD was established. We have ruled out paraneoplastic, inflammatory, and infectious causes, as well as ischemic events. Her medical history showed a CCA and frontal teratoma. We administered tolvaptan initially at a low dosage (15 mg once a day) with persistence of hyponatremia. Therefore, the dosage was first doubled (30 mg once a day) and then increased to 45 mg once a day with an initial improvement in serum sodium levels, although not long-lasting. We therefore tried dividing the 45 mg tolvaptan administration into two doses of 30 mg and 15 mg respectively, using an off-label treatment schedule, thus achieving long-lasting serum sodium levels in the low-normal range associated with a general clinical improvement. Conclusions: This report underlines the importance of the correct diagnosis, management and treatment of SIAD, as well as the need for further studies about the pharmacokinetics and pharmacodynamics of vasopressin receptor antagonists.

Randomized, Double Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Tolvaptan in Chinese Patients with Hyponatremia Caused by Siadh

Tolvaptan Therapy of Chinese Cirrhotic Patients with Ascites after Insufficient Diuretic Routine Medication Responses: a Phase III Clinical Trial

Utility and Safety of Tolvaptan in Cirrhotic Patients with Hyponatremia: a Prospective Cohort Study

Efficacy and safety of selective arginine vasopressin V2 receptor antagonist for the syndrome of inappropriate antidiuretic hormone secretion

A new method of intermittent lower dose of tolvaptan combined with fluid restriction to treat the syndrome of inappropriate antidiuresis: A case report.

Pharmacokinetics, pharmacodynamics and safety of 15 mg-tolvaptan administered orally for 7 consecutive days to Chinese patients with child-Pugh B cirrhosis

Tolvaptan and the role of kidney aquaporin-2 abundance in managing volume overload in patients with CKD

Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD

The Effect of Tolvaptan on Metabolism and Electrolyte Homeostasis in Patients with Heart Failure: A Systematic Review and Meta-Analysis

[A Randomized, Double-Blind, Double-Dummy Study Comparing a Fixed Dose Combination of Telmisartan 80 Mg Plus Hydrochlorothiazide 12.5 Mg to Telmisartan 80 Mg in Chinese Hypertensive Patients Who Failed to Respond Adequately to Telmisartan 80 Mg].

Review on pharmacoeconomics evaluation studies on treatment of tolvaptan on hyponatremia

Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload

Safety and Efficacy of Tolvaptan for the Prevention of Contrast-Induced Acute Kidney Injury in Patients with Heart Failure and Chronic Kidney Disease

Preliminary Report of Intravenous Tolvaptan Sodium Phosphate (Samtas®) Treatment in Decompensated Heart Failure

BSC1 inhibition complements effects of vasopressin V2 receptor antagonist on hyponatremia in SIADH rats

Tolvaptan therapy to treat severe hyponatremia in pediatric nephrotic syndrome

Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial

The potential effectiveness of tolvaptan in critically ill patients including cardiac and noncardiac populations: a retrospective observational study

Efficacy of tolvaptan for fluid management after cardiovascular surgery: A systematic review and meta-analysis of randomized control trials

The role of tolvaptan add-on therapy in patients with acute heart failure: a systematic review and network meta-analysis

The Safety and Efficacy of Tolvaptan in the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-analysis